Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Regeneron’s EYLEA HD® 8 mg Shows Promise for Retinal Vein Occlusion in Phase 3 QUASAR Trial

Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...

February 10, 2025 | Monday | News
Revive Therapeutics Focuses on Bucillamine for Medical Countermeasures and Nerve Agent Exposure Treatment

 Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences com...

February 04, 2025 | Tuesday | News
Eisai and Biogen Provide Update on Lecanemab’s EU Regulatory Review for Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

February 04, 2025 | Tuesday | News
China’s NMPA Approves Sarclisa for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...

February 03, 2025 | Monday | News
GHIT Fund Announces JPY 2 Billion Investment in New Diagnostics and Drugs for Neglected Tropical Diseases and Malaria

The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight...

January 30, 2025 | Thursday | News
Neurocrine Biosciences Secures Global Rights to Osavampator, a Potential Breakthrough Treatment for Major Depressive Disorder

 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...

January 28, 2025 | Tuesday | News
Merck and Eisai Announce Promising Interim Results from LEAP-015 Trial of KEYTRUDA® and LENVIMA® in HER2-Negative Gastroesophageal Adenocarcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...

January 27, 2025 | Monday | News
Eli Lilly Secures FDA Approval for Omvoh® to Treat Moderately to Severely Active Crohn’s Disease

 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

January 16, 2025 | Thursday | News
Advanced Genomics APAC Partners with Cancer Precision Medicine to Launch GALEAS™ Bladder Cancer Screening Test in Japan

Advanced Genomics APAC Co., Ltd. (hereinafter referred to as "Advanced Genomics APAC," headquartered in Taiwan, Managing Director: Andy Chang) is pl...

January 15, 2025 | Wednesday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
Japan-Based Meiji Seika Pharma Invests $20 Million in U.S.-Based MPM BioImpact to Drive Innovations in Virology and Biotech

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...

January 13, 2025 | Monday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Primo Biotechnology Partners with SHINE Technologies to Distribute Ilumira® in Asia-Pacific

Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...

January 09, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close